Diclofenamide - Strongbridge Biopharma/Taro Pharmaceutical

Drug Profile

Diclofenamide - Strongbridge Biopharma/Taro Pharmaceutical

Alternative Names: Daranide; Dichlorphenamide; Keveyis

Latest Information Update: 12 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Taro Pharmaceutical Industries
  • Class Antiglaucomas; Small molecules; Sulfonamides
  • Mechanism of Action Carbonic anhydrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Paralysis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Paralysis
  • Market Withdrawal Glaucoma

Most Recent Events

  • 05 Mar 2018 Pooled efficacy data from two phase III trials in Paralysis released by Strongbridge Biopharma
  • 01 Mar 2018 Strongbridge Biopharma completes enrolment in two phase III trials for Paralysis (In adolescents), before March 2018
  • 01 Jan 2018 Strongbridge Biopharma initiated enrolment in two phase III trials for Paralysis (In adolescents), before January 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top